ImmunoGen, Inc.
ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS
Last updated:
Abstract:
Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
Status:
Application
Type:
Utility
Filling date:
15 Jan 2021
Issue date:
27 May 2021